StreetInsider.com News Articles

Form 6-K CollPlant Biotechnologie For: May 29

Fri, 29 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260529/26570726.html

Form 6-K CollPlant Biotechnologie For: May 29

Fri, 29 May 2026 07:11:00 -0400

si-local-file:///var/storage/secattach/20260529/26570726.html

CollPlant (CLGN) Tops Q1 EPS by 3c

Fri, 29 May 2026 07:04:21 -0400

CollPlant (NASDAQ: CLGN) reported Q1 EPS of ($0.21), $0.03 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $73 thousand versus the consensus estimate of $460 thousand.

For earnings history and earnings-related data on CollPlant (CLGN) click here.

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

REHOVOT, Israel, May 29, 2026 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and medical aesthetics company developing innovative technologies and products based on its non-animal-derived recombinant human collagen (rhCollagen) for tissue regeneration and medical aesthetics applications, today announced financial results for the first quarter of 2026 and provided a corporate update.

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

COLLPLANT BIOTECHNOLOGIES REPORTS 2026 FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Fri, 29 May 2026 07:00:00 -0400

Form 3 CollPlant Biotechnologie For: Mar 18 Filed by: Evans Hugh M

Mon, 27 Apr 2026 15:40:00 -0400

si-local-file:///var/storage/secattach/20260427/26374310.html

Form 3 CollPlant Biotechnologie For: Mar 18 Filed by: Evans Hugh M

Mon, 27 Apr 2026 15:40:00 -0400

si-local-file:///var/storage/secattach/20260427/26374310.html

Form EFFECT CollPlant Biotechnologie

Wed, 22 Apr 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260422/26346562.html

Form EFFECT CollPlant Biotechnologie

Wed, 22 Apr 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260422/26346562.html

Form 424B3 CollPlant Biotechnologie

Tue, 21 Apr 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260421/26345082.html

Form 424B3 CollPlant Biotechnologie

Tue, 21 Apr 2026 16:58:00 -0400

si-local-file:///var/storage/secattach/20260421/26345082.html

CollPlant (CLGN) files for 3.3M share offering by selling stockholders

Wed, 15 Apr 2026 16:20:27 -0400

CollPlant (NASDAQ: CLGN) has filed for up to 3,296,000 share offering by selling stockholders.

CollPlant (CLGN) files for 3.3M share offering by selling stockholders

Wed, 15 Apr 2026 16:20:27 -0400

CollPlant (NASDAQ: CLGN) has filed for up to 3,296,000 share offering by selling stockholders.

Form F-1/A CollPlant Biotechnologie

Wed, 15 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260415/26318703.html

Form F-1/A CollPlant Biotechnologie

Wed, 15 Apr 2026 16:18:00 -0400

si-local-file:///var/storage/secattach/20260415/26318703.html

Form 6-K CollPlant Biotechnologie For: Apr 13

Mon, 13 Apr 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260413/26302789.html

Form 6-K CollPlant Biotechnologie For: Apr 13

Mon, 13 Apr 2026 07:21:00 -0400

si-local-file:///var/storage/secattach/20260413/26302789.html

CollPlant terminates AbbVie partnership, cuts workforce by 50%

Mon, 13 Apr 2026 07:01:44 -0400

CollPlant Biotechnologies Ltd. (NASDAQ: CLGN) announced that AbbVie terminated their development agreement and the company will reduce its workforce by approximately 50% as part of cost-reduction measures.

Allergan Industrie SAS, an AbbVie company, exercised its right to terminate the development agreement with 60 days' advance notice. The partnership, which began in February 2021, involved AbbVie developing a dermal and soft tissue filler product using CollPlant's recombinant human collagen technology for the medical aesthetics market.

Chief Executive Officer Yehiel Tal stated in a shareholder letter that the company is implementing a cost-reduction and workforce optimization plan. The measures are expected to extend the

CollPlant terminates AbbVie partnership, cuts workforce by 50%

Mon, 13 Apr 2026 07:01:44 -0400

Chief Executive Officer Yehiel Tal stated in a shareholder letter that the company is implementing a cost-reduction and workforce optimization plan. The measures are expected to extend the

CollPlant Issues Letter to Shareholders

Mon, 13 Apr 2026 07:00:00 -0400

REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal.

Dear Shareholders,

This morning,

CollPlant Issues Letter to Shareholders

Mon, 13 Apr 2026 07:00:00 -0400

Dear Shareholders,

This morning,

CollPlant Issues Letter to Shareholders

Mon, 13 Apr 2026 07:00:00 -0400

Dear Shareholders,

This morning,

CollPlant Issues Letter to Shareholders

Mon, 13 Apr 2026 07:00:00 -0400

Dear Shareholders,

This morning,